Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 909-916

  Gonzalez Angulo, A M ^a   Liu, S ^a   Chen, H ^a   Chavez MacGregor, M ^a   Sahin, A ^a   Hortobagyi, G N ^a   Mills, G B ^a   Do, K A ^a   Meric Bernstam, F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Residual disease

Indexed keywords

CAVEOLIN 1; CD31 ANTIGEN; CHECKPOINT KINASE 1; CYCLIN E; CYCLIN E1; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; PROTEIN CHK1PS345; PROTEIN RAB25; RAB PROTEIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; FUNCTIONAL PROTEOMICS; HORMONE RECEPTOR POSITIVE BREAST CANCER; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN MICROARRAY; RECURRENCE FREE SURVIVAL; RESIDUAL BREAST CANCER; RISK ASSESSMENT; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; PROTEIN ARRAY ANALYSIS; PROTEOMICS; TAXOIDS;

EID: 84875603543     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds530     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
3. Bear HD, Anderson S, Smith RE et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24: 2019-2027.
4. Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037-1044.
5. Symmans WF, Peintinger F, Hatzis C et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007; 25: 4414-4422.
6. O'Regan RM, Von Roenn JH, Carlson RW et al. Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer. Clin Breast Cancer 2005; 6: 163-168.
7. Stearns V, Singh B, Tsangaris T et al. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 2003; 9: 124-133.
8. Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004; 10: 6622-6628.
9. Hennessy BT, Lu Y, Gonzalez-Angulo AM et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics 2010; 6: 129-151.
10. Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F et al. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 2011; 8: 11.
11. Hu J, He X, Baggerly KA et al. Non-parametric quantification of protein lysate arrays. Bioinformatics 2007; 23: 1986-1994.
12. Residual Cancer Burden Calculator. http://www3.mdanderson.org/app/medcalc/ index.cfm?pagename=jsconvert3 (26 April 2012, date last accessed).
13. Neeley ES, Kornblau SM, Coombes KR et al. Variable slope normalization of reverse phase protein arrays. Bioinformatics 2009; 25: 1384-1389.
14. Guarneri V, Piacentini F, Ficarra G et al. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Ann Oncol 2009; 20: 1193-1198.
15. Mittendorf EA, Wu Y, Scaltriti M et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009; 15: 7381-7388.
16. Creighton CJ, Li X, Landis M et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009; 106: 13820-13825.
17. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 2001; 21: 4129-4139.
18. Liu Q, Guntuku S, Cui XS et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Develop 2000; 14: 1448-1459.
19. Merry C, Fu K, Wang J et al. Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle 2010; 9: 279-283.
20. Agarwal R, Jurisica I, Mills GB et al. The emerging role of the RAB25 small GTPase in cancer. Traffic 2009; 10: 1561-1568.
21. Cheng JM, Ding M, Aribi A et al. Loss of RAB25 expression in breast cancer. Int J Cancer 2006; 118: 2957-2964.
22. Chin K, Devries S, Fridlyand J et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006; 10: 529-541.
23. Williams TM, Lee H, Cheung MW et al. Combined loss of INK4a and caveolin-1 synergistically enhances cell proliferation and oncogene-induced tumorigenesis: role of INK4a/CAV-1 in mammary epithelial cell hyperplasia. J Biol Chem 2004; 279: 24745-24756.
24. Sagara Y, Mimori K, Yoshinaga K et al. Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer. Br J Cancer 2004; 91: 959-965.
25. Hayashi K, Matsuda S, Machida K et al. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 2001; 61: 2361-2364.
26. Li T, Sotgia F, Vuolo MA et al. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am J Pathol 2006; 168: 1998-2013.
27. Seshadri R, Lee CS, Hui R et al. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res 1996; 2: 1177-1184.
28. Bieche I, Olivi M, Nogues C et al. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer 2002; 86: 580-586.
29. Keyomarsi K, Tucker SL, Buchholz TA et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347: 1566-1575.
30. Span PN, Tjan-Heijnen VC, Manders P et al. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 2003; 22: 4898-4904.
31. Agarwal R, Gonzalez-Angulo AM, Myhre S et al. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 2009; 15: 3654-3662.
32. ClinicalTrials.gov. http://www.clinicaltrials.org/ (26 April 2012, date last accessed).